Lanreotide as Treatment of Polycystic Livers (LOCKCYST)
Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers
Sponsor: Ipsen
Listed as NCT00565097, this PHASE2/PHASE3 trial focuses on Hepatomegaly and Liver Diseases and remains completed. Sponsored by Ipsen, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Mar 2022 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Mar 2022 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
First recorded
Oct 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ipsen
- Radboud University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .